Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 33

1.

Restriction Spectrum Imaging Differentiates True Tumor Progression From Immune-Mediated Pseudoprogression: Case Report of a Patient With Glioblastoma.

Daghighi S, Bahrami N, Tom WJ, Coley N, Seibert TM, Hattangadi-Gluth JA, Piccioni DE, Dale AM, Farid N, McDonald CR.

Front Oncol. 2020 Jan 28;10:24. doi: 10.3389/fonc.2020.00024. eCollection 2020.

2.

ANG1005, a brain penetrating peptide-drug conjugate, shows activity in patients with breast cancer with leptomeningeal carcinomatosis and recurrent brain metastases.

Kumthekar P, Tang SC, Brenner AJ, Kesari S, Piccioni DE, Anders CK, Carrillo JA, Chalasani P, Kabos P, Puhalla SL, Tkaczuk KHR, Garcia A, Ahluwalia MS, Wefel JS, Lakhani N, Ibrahim NK.

Clin Cancer Res. 2020 Jan 22. pii: clincanres.3258.2019. doi: 10.1158/1078-0432.CCR-19-3258. [Epub ahead of print]

3.

Molecular profiling of cancer patients enables personalized combination therapy: the I-PREDICT study.

Sicklick JK, Kato S, Okamura R, Schwaederle M, Hahn ME, Williams CB, De P, Krie A, Piccioni DE, Miller VA, Ross JS, Benson A, Webster J, Stephens PJ, Lee JJ, Fanta PT, Lippman SM, Leyland-Jones B, Kurzrock R.

Nat Med. 2019 May;25(5):744-750. doi: 10.1038/s41591-019-0407-5. Epub 2019 Apr 22.

4.

Analysis of cell-free circulating tumor DNA in 419 patients with glioblastoma and other primary brain tumors.

Piccioni DE, Achrol AS, Kiedrowski LA, Banks KC, Boucher N, Barkhoudarian G, Kelly DF, Juarez T, Lanman RB, Raymond VM, Nguyen M, Truong JD, Heng A, Gill J, Saria M, Pingle SC, Kesari S.

CNS Oncol. 2019 Jun;8(2):CNS34. doi: 10.2217/cns-2018-0015. Epub 2019 Mar 11.

5.

Identifying early diffusion imaging biomarkers of regional white matter injury as indicators of executive function decline following brain radiotherapy: A prospective clinical trial in primary brain tumor patients.

Tringale KR, Nguyen T, Bahrami N, Marshall DC, Leyden KM, Karunamuni R, Seibert TM, Kay Gorman M, Connor M, Burkeen J, Piccioni DE, Farid N, Hattangadi-Gluth JA, McDonald CR.

Radiother Oncol. 2019 Mar;132:27-33. doi: 10.1016/j.radonc.2018.11.018. Epub 2018 Dec 20.

6.

Infliximab for treatment-refractory transverse myelitis following immune therapy and radiation.

Chang VA, Simpson DR, Daniels GA, Piccioni DE.

J Immunother Cancer. 2018 Dec 22;6(1):153. doi: 10.1186/s40425-018-0471-2.

7.

Telomerase reverse transcriptase promoter alterations across cancer types as detected by next-generation sequencing: A clinical and molecular analysis of 423 patients.

Schwaederle M, Krishnamurthy N, Daniels GA, Piccioni DE, Kesari S, Fanta PT, Schwab RB, Patel SP, Parker BA, Kurzrock R.

Cancer. 2018 Mar 15;124(6):1288-1296. doi: 10.1002/cncr.31175. Epub 2017 Dec 6.

8.

Next-Generation Sequencing in the Clinical Setting Clarifies Patient Characteristics and Potential Actionability.

Bieg-Bourne CC, Millis SZ, Piccioni DE, Fanta PT, Goldberg ME, Chmielecki J, Parker BA, Kurzrock R.

Cancer Res. 2017 Nov 15;77(22):6313-6320. doi: 10.1158/0008-5472.CAN-17-1569. Epub 2017 Sep 22.

9.

Erratum to: Imaging correlates for the 2016 update on WHO classification of grade II/III gliomas: implications for IDH, 1p/19q and ATRX status.

Delfanti RL, Piccioni DE, Handwerker J, Bahrami N, Krishnan A, Karunamuni R, Hattangadi-Gluth JA, Seibert TM, Srikant A, Jones KA, Snyder VS, Dale AM, White NS, McDonald CR, Farid N.

J Neurooncol. 2017 Dec;135(3):611. doi: 10.1007/s11060-017-2620-8.

PMID:
28905256
10.

Imaging correlates for the 2016 update on WHO classification of grade II/III gliomas: implications for IDH, 1p/19q and ATRX status.

Delfanti RL, Piccioni DE, Handwerker J, Bahrami N, Krishnan A, Karunamuni R, Hattangadi-Gluth JA, Seibert TM, Srikant A, Jones KA, Snyder VS, Dale AM, White NS, McDonald CR, Farid N.

J Neurooncol. 2017 Dec;135(3):601-609. doi: 10.1007/s11060-017-2613-7. Epub 2017 Sep 4. Erratum in: J Neurooncol. 2017 Sep 13;:.

11.

Genomic Alterations in Circulating Tumor DNA from Diverse Cancer Patients Identified by Next-Generation Sequencing.

Schwaederle M, Chattopadhyay R, Kato S, Fanta PT, Banks KC, Choi IS, Piccioni DE, Ikeda S, Talasaz A, Lanman RB, Bazhenova L, Kurzrock R.

Cancer Res. 2017 Oct 1;77(19):5419-5427. doi: 10.1158/0008-5472.CAN-17-0885. Epub 2017 Aug 14.

12.

Anxiety and Depression Associated With Burden in Caregivers of Patients With Brain Metastases.

Saria MG, Courchesne NS, Evangelista L, Carter JL, MacManus DA, Gorman MK, Nyamathi AM, Phillips LR, Piccioni DE, Kesari S, Maliski SL.

Oncol Nurs Forum. 2017 May 1;44(3):306-315. doi: 10.1188/17.ONF.306-315.

PMID:
28635984
13.

Restriction Spectrum Imaging Improves Risk Stratification in Patients with Glioblastoma.

Krishnan AP, Karunamuni R, Leyden KM, Seibert TM, Delfanti RL, Kuperman JM, Bartsch H, Elbe P, Srikant A, Dale AM, Kesari S, Piccioni DE, Hattangadi-Gluth JA, Farid N, McDonald CR, White NS.

AJNR Am J Neuroradiol. 2017 May;38(5):882-889. doi: 10.3174/ajnr.A5099. Epub 2017 Mar 9.

14.

Glioblastoma in the elderly: treatment patterns and survival.

Pretanvil JA, Salinas IQ, Piccioni DE.

CNS Oncol. 2017 Jan;6(1):19-28. doi: 10.2217/cns-2016-0023. Epub 2016 Dec 21.

15.

Use of Liquid Biopsies in Clinical Oncology: Pilot Experience in 168 Patients.

Schwaederle M, Husain H, Fanta PT, Piccioni DE, Kesari S, Schwab RB, Patel SP, Harismendy O, Ikeda M, Parker BA, Kurzrock R.

Clin Cancer Res. 2016 Nov 15;22(22):5497-5505. doi: 10.1158/1078-0432.CCR-16-0318. Epub 2016 May 16.

16.

Restriction spectrum imaging predicts response to bevacizumab in patients with high-grade glioma.

McDonald CR, Delfanti RL, Krishnan AP, Leyden KM, Hattangadi-Gluth JA, Seibert TM, Karunamuni R, Elbe P, Kuperman JM, Bartsch H, Piccioni DE, White NS, Dale AM, Farid N.

Neuro Oncol. 2016 Nov;18(11):1579-1590. Epub 2016 Apr 21.

17.

Precision Oncology: The UC San Diego Moores Cancer Center PREDICT Experience.

Schwaederle M, Parker BA, Schwab RB, Daniels GA, Piccioni DE, Kesari S, Helsten TL, Bazhenova LA, Romero J, Fanta PT, Lippman SM, Kurzrock R.

Mol Cancer Ther. 2016 Apr;15(4):743-52. doi: 10.1158/1535-7163.MCT-15-0795. Epub 2016 Feb 12.

18.

Detection rate of actionable mutations in diverse cancers using a biopsy-free (blood) circulating tumor cell DNA assay.

Schwaederle M, Husain H, Fanta PT, Piccioni DE, Kesari S, Schwab RB, Banks KC, Lanman RB, Talasaz A, Parker BA, Kurzrock R.

Oncotarget. 2016 Mar 1;7(9):9707-17. doi: 10.18632/oncotarget.7110.

19.

PPX and Concurrent Radiation for Newly Diagnosed Glioblastoma Without MGMT Methylation: A Randomized Phase II Study: BrUOG 244.

Elinzano H, Glantz M, Mrugala M, Kesari S, Piccioni DE, Kim L, Pan E, Yunus S, Coyle T, Timothy K, Evans D, Mantripragada K, Boxerman J, DiPetrillo T, Donahue JE, Hebda N, Mitchell KM, Rosati KL, Safran H.

Am J Clin Oncol. 2018 Feb;41(2):159-162. doi: 10.1097/COC.0000000000000247.

PMID:
26658237
20.

Molecular inimitability amongst tumors: implications for precision cancer medicine in the age of personalized oncology.

Patel SP, Schwaederle M, Daniels GA, Fanta PT, Schwab RB, Shimabukuro KA, Kesari S, Piccioni DE, Bazhenova LA, Helsten TL, Lippman SM, Parker BA, Kurzrock R.

Oncotarget. 2015 Oct 20;6(32):32602-9. doi: 10.18632/oncotarget.5289.

21.

Molecular profiling of gliomas: potential therapeutic implications.

Alentorn A, Duran-Peña A, Pingle SC, Piccioni DE, Idbaih A, Kesari S.

Expert Rev Anticancer Ther. 2015;15(8):955-62. doi: 10.1586/14737140.2015.1062368. Epub 2015 Jun 28. Review.

PMID:
26118895
22.

Next generation sequencing demonstrates association between tumor suppressor gene aberrations and poor outcome in patients with cancer.

Schwaederle M, Daniels GA, Piccioni DE, Kesari S, Fanta PT, Schwab RB, Shimabukuro KA, Parker BA, Kurzrock R.

Cell Cycle. 2015;14(11):1730-7. doi: 10.1080/15384101.2015.1033596.

23.

On the Road to Precision Cancer Medicine: Analysis of Genomic Biomarker Actionability in 439 Patients.

Schwaederle M, Daniels GA, Piccioni DE, Fanta PT, Schwab RB, Shimabukuro KA, Parker BA, Kurzrock R.

Mol Cancer Ther. 2015 Jun;14(6):1488-94. doi: 10.1158/1535-7163.MCT-14-1061. Epub 2015 Apr 7.

24.

Cyclin alterations in diverse cancers: Outcome and co-amplification network.

Schwaederlé M, Daniels GA, Piccioni DE, Fanta PT, Schwab RB, Shimabukuro KA, Parker BA, Kurzrock R.

Oncotarget. 2015 Feb 20;6(5):3033-42.

25.

Mitochondrial p32 is upregulated in Myc expressing brain cancers and mediates glutamine addiction.

Fogal V, Babic I, Chao Y, Pastorino S, Mukthavaram R, Jiang P, Cho YJ, Pingle SC, Crawford JR, Piccioni DE, Kesari S.

Oncotarget. 2015 Jan 20;6(2):1157-70.

26.

Retrospective analysis of safety and feasibility of a 3 days on/11 days off temozolomide dosing regimen in recurrent adult malignant gliomas.

van Vugt VA, Piccioni DE, Brown BD, Brown T, Saria MG, Juarez T, Kesari S.

CNS Oncol. 2014 Jul;3(4):257-65. doi: 10.2217/cns.14.29.

27.

Deferred use of bevacizumab for recurrent glioblastoma is not associated with diminished efficacy.

Piccioni DE, Lai A.

Neuro Oncol. 2014 Oct;16(10):1427-8. doi: 10.1093/neuonc/nou214. Epub 2014 Aug 25. No abstract available.

28.

Concurrent intrathecal methotrexate and liposomal cytarabine for leptomeningeal metastasis from solid tumors: a retrospective cohort study.

Scott BJ, van Vugt VA, Rush T, Brown T, Chen CC, Carter BS, Schwab R, Fanta P, Helsten T, Bazhenova L, Parker B, Pingle S, Saria MG, Brown BD, Piccioni DE, Kesari S.

J Neurooncol. 2014 Sep;119(2):361-8. doi: 10.1007/s11060-014-1486-2. Epub 2014 Jun 19.

PMID:
24942463
29.

Deferred use of bevacizumab for recurrent glioblastoma is not associated with diminished efficacy.

Piccioni DE, Selfridge J, Mody RR, Chowdhury R, Li S, Lalezari S, Wawrzynski J, Quan J, Zurayk M, Chou AP, Sanchez DE, Liau LM, Ellingson BM, Pope WB, Nghiemphu PL, Green RM, Wang HJ, Yong WH, Elashoff R, Cloughesy TF, Lai A.

Neuro Oncol. 2014 Jun;16(6):815-22. doi: 10.1093/neuonc/nou028. Epub 2014 Mar 13.

30.

Clinical trials of viral therapy for malignant gliomas.

Piccioni DE, Kesari S.

Expert Rev Anticancer Ther. 2013 Nov;13(11):1297-305. doi: 10.1586/14737140.2013.851160. Epub 2013 Oct 21. Review.

PMID:
24138481
31.

Comparison of the total length and areas of upper central incisors between males and females using computer-assisted morphometry.

Teixeira VP, Rodrigues DB, Reis MA, Castro EC, Piccioni DE, Beghini M, de Lima Pereira SA.

Anat Sci Int. 2013 Jun;88(3):130-3. doi: 10.1007/s12565-013-0174-1. Epub 2013 Apr 2.

PMID:
23546874
32.

Identification of retinol binding protein 1 promoter hypermethylation in isocitrate dehydrogenase 1 and 2 mutant gliomas.

Chou AP, Chowdhury R, Li S, Chen W, Kim AJ, Piccioni DE, Selfridge JM, Mody RR, Chang S, Lalezari S, Lin J, Sanchez DE, Wilson RW, Garrett MC, Harry B, Mottahedeh J, Nghiemphu PL, Kornblum HI, Mischel PS, Prins RM, Yong WH, Cloughesy T, Nelson SF, Liau LM, Lai A.

J Natl Cancer Inst. 2012 Oct 3;104(19):1458-69. doi: 10.1093/jnci/djs357. Epub 2012 Sep 3.

33.

Internal Movement of Erwinia amylovora Through Symptomless Apple Scion Tissues into the Rootstock.

Momol MT, Norelli JL, Piccioni DE, Momol EA, Gustafson HL, Cummins JN, Aldwinckle HS.

Plant Dis. 1998 Jun;82(6):646-650. doi: 10.1094/PDIS.1998.82.6.646.

PMID:
30857015

Supplemental Content

Loading ...
Support Center